BenevolentAI

BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of...Read more

Industries

Stage

Private Equity

Employees

201-500

Links

Org chart

Ivan Griffin
Co-founder and COO
Anne Phelan
Chief Scientific Officer
Daniel Neil
SVP Artificial Intelligence
Mark Davies
SVP Informatics and Data
Will Scrimshaw
General Counsel
Nikki Robas
VP Drug Discovery
Peter Cox
VP Drug Discovery
Dave Michalovich
SVP, Precision Medicine
Bryn Williams-Jones
VP Drug Discovery
Ed Savory
VP Drug Discovery
Peter Richardson
VP Pharmacology
Catherine Tucker
VP, Business Development
Rajin Kang
VP Communications